GVHD is a life-threatening complication of allogeneic BMT. It can be either acute (aGVHD) or chronic (cGVHD), In our BMT Unit, we have observed a high frequency with the latter form behaving like an autoimmune disease. of skin rash associated with fever and other clinical finClassically, GVHD is thought to be the response of donor dings during engraftment of autologous BM and/or lymphocytes to the foreign histocompatibility antigens of PBSC. Thirty patients with breast cancer and 12 the recipients. 1 Recent studies in humans, however, indicate patients with Hodgkin's or non-Hodgkin's lymphoma, that aGVHD-like syndrome can occur after BMT perfortreated with the same regimen, were analyzed retromed between identical twins (syngeneic) or after ABMT.
Patients and methods
negative viral, fungal and bacterial cultures obtained at the time of bronchoscopy. Skin biopsy specimens were obtained from 10 patients The charts of 30 patients with breast cancer and 12 patients with Hodgkin's (HD) or non-Hodgkin's lymphoma (NHL) and were reviewed. The diagnosis and grading of GVHD features were performed according to published criteria. were reviewed. Between July 1991 and September 1995, all the patients were treated consecutively in our BMTU with one regimen of high-dose chemotherapy (STAMP V), Statistical analysis which included cytoxan 6000 mg/m 2 , carboplatin 800 Proportions of patients developing various problems (rash, mg/m 2 , and thiotepa 600 mg/m 2 given by continuous fever, PTR) within 14 days of transplant were compared infusion over 96 h. Fifteen breast cancer and seven lymbetween strata defined by variables of interest (gender, canphoma patients received both BM and PBSC and the cer type, use of BM, number of previous chemotherapy remainder of the patients, after July 1994, received only regimens, number of mononuclear cells reinfused) using PBSC. PBSC mobilization was performed using standard
Fisher's exact test. Exact odds ratios (OR) and correspondchemotherapy and G-CSF given subcutaneously starting 4 ing 95% confidence intervals (CI) for developing a rash days after chemotherapy. For patients undergoing PBSC were estimated for each stratifying variable using the transplantation, 16-18 l leukaphereses were performed, EGRET epidemiological statistics software package while those patients undergoing bone marrow and PBSC (SERC, Seattle, WA, USA). Exact ORs for developing a transplantation had two standard 10 l leukaphereses. The fever and PTR were also estimated for cancer type and bone following data were collected: patient characteristics (Table  marrow infusion. Exact stratified ORs were estimated for 1), time to recovery of WBC which is defined as any developing each of the three types of problem (rash, fever, increase in WBC from nadir of р200/l, and time to AGC PTR), stratifying bone marrow use by cancer type and vice Ͼ500/l, time to recovery of platelets Ͼ20 000/l, freversa. In addition, the Wilcoxon rank sum test was used to quency of RBC and platelet transfusions, time to platelet compare statistically the number of platelet infusions and transfusion refractoriness (PTR), time of appearance and the length of hospital stay between patients who developed resolution of skin rash, results of skin biopsy, treatments the autoaggression syndrome and patients who did not. The for skin rash and/or platelet transfusion refractoriness.
Wilcoxon signed rank test was used to compare within The definition of PTR included the increase in platelet patients the time to onset of skin rash and time to increased transfusion requirement to у1 transfusion a day every day WBC above nadir. with either no increase in platelet count at 1 h after transfusion, or a transient increase within р24 h. All patients with PTR were tested for anti-HLA antibodies and crossResults match anti-platelet antibodies. Routine screening for anti-HLA antibodies was performed on all patients before the Description of the syndrome transplant.
Diffuse alveolar hemorrhage (DAH) was defined cliniTypically, maculopapular rash which involves the body and extremities with or without temperature elevation (up to cally and bronchoscopically. The definition included hemoptysis with hypoxia and pulmonary infiltrates on chest X-40°C) appears within 1-2 days around the time the WBC shows increase from a nadir of 100-200/l. Only one ray as well as bloody excretions on bronchoscopy with patient with vancomycin-related rash was not included in the group of patients with the syndrome. In patients developing skin rash, the median and range for time to The median time to increase in WBC was identical for patients overall (n = 42) as well as only those with rash (n = 23). Figure 1 . Usually, the treat- with those without it (median 5, range 1-57). The median number of platelet transfusions for those with PTR was 14 (range 9-102). Only one patient without the autoaggression prednisolone successfully. The fourth patient was not treated with steroids and died on the ventilator with a diagsyndrome developed PTR with a total of 57 platelet transfusions. Seven patients with PTR tested positive for antinosis of acute respiratory distress syndrome (ARDS). Diarrhea with the syndrome was usually seen after HLA antibodies and/or indirect antiplatelet antibodies; four of these were tested while patients were receiving intraimprovement in the initial chemotherapy-related diarrhea and was closely associated with fever and rash, and without venous immunoglobulin for the treatment of PTR and had multiple nonspecific antibodies. Each of the other three infectious etiology. Significant diarrhea (Ͼ1000 cc/day) was seen in five patients (Table 3) . patients had specific anti-HLA antibodies: anti-A2, anti-B18 and anti-B15. On the other hand, three patients without Two patients had prolonged thrombocytopenia (beyond day 50 after transplant) and bone marrow aspiration and PTR had antibodies, two with anti-HLA antibodies and one with crossmatch antiplatelet antibodies.
biopsy revealed increased numbers of megakaryocytes, compatible with a diagnosis of autoimmune thrombocytoOther, less frequent manifestations of the syndrome are shown in Table 3 . All these manifestations were seen in penia. In both cases, steroid therapy was initiated with resolution of the thrombocytopenia. patients with breast cancer. Four patients (9.5% of all patients) with persistent fever and increasing confluence of One patient had a transient episode of autoimmune cold agglutinin hemolytic anemia associated with rash and fever. the rash developed hypoxia, cough and hemoptysis with patchy interstitial infiltrates on chest X-ray. These patients All resolved without treatment. It is important to note that the syndrome was frequently transient without therapy, and looked acutely sick, were in respiratory distress, and had labile blood pressure with tachypnea and tachycardia. Bronthe median time to resolution of the skin rash was 5 days (range 3-10). However, the median length of hospital stay choscopy and bronchoalveolar lavage were performed and showed bloody secretions with mucosal edema but negative for patients with the syndrome (31 days, range 21-47) was significantly (P = 0.0008) longer than that for patients withstains for organisms and negative cultures. Two patients required ventilatory support. Three patients were diagnosed out the syndrome (23 days, range 16-71 days). as suffering from DAH and treated with high-dose methyl-
Frequency of the syndrome
A total of 23 patients (55%) out of 42 patients analyzed had skin rashes. Eighteen (43%) had fever, and 13 patients (31%) had PTR. Table 4 shows the incidence of these symptoms and signs by disease category and stem cell source. It is clear that a higher proportion of breast cancer patients developed the syndrome in comparison to lymphoma patients (67% vs 25%; P = 0.051). In addition, breast cancer patients were likely to have fever with the syndrome (OR 13.58, 95% CI 1.61-654.45, P = 0.005), and had significantly higher risk if they received BM+PBSC (OR 12.34, 95% CI 1.11-692.2, P = 0.027). Higher incidence of PTR was also seen with BM+PBSC transplants but did not reach statistical significance (OR 4.95, , P = 0.065) ( Table 4) . all biopsies were performed in breast cancer patients WBC began at day 7 for two patients and at day 9 for one patient postreflects the higher frequency of these patients in our BMTU reinfusion of stem cells. Eventually, all patients recovered their Plt count to above 20 000/l and became independent of Plt transfusions.
The results of skin biopsy
as well as the higher frequency of the rash in these patients. All biopsies were reviewed again for the purpose of this category (P = 0.02) and number of previous chemo/ radiotherapy regimens (P = 0.002) as predictive factors for report and the original interpretations were confirmed. The diagnosis of acute GVHD was established in six cases, developing the autoaggression syndrome, with the odds ratios of 5.7 and 9.9, respectively ( Table 5 ). The relatively while the rest were interpreted as drug eruption (two), perifolliculitis (one), or not diagnostic (one). The histologic large width of some confidence intervals reflects the relatively low precision of corresponding estimated odds ratios features required for a diagnosis of acute GVHD were the presence of necrotic keratinocytes and satellite cell granted by this sample size. The clinical relevance of differences in syndrome rates which are found to be statistically necrosis, vacuolar interface dermatitis and sparse superficial perivascular lymphocytic infiltration. GVHD was hissignificant should be judged by examining the confidence interval bound closest to the estimated odds ratio. Thus, the tologically either grade I, grade I-II, or grade II in two, three, and one patients, respectively.
lower 95% confidence bound of 1.11 for the breast cancer vs lymphoma syndrome risk odds ratio indicates that we Although histologic features of GVHD were absent in four cases, these patients had the clinical picture of the syncan be 95% confident that the odds of a breast cancer patient experiencing the syndrome are at least 11% greater drome and were analyzed as such.
than the corresponding odds for a lymphoma patient. The lower 95% confidence bound of 2.11 for the one treatment Treatment with steroids regimen vs two or more treatment regimens syndrome risk odds ratio indicates that we can be 95% confident that the Three patients with DAH were treated according to published protocols 16 using 1 g/day of methylprednisolone odds that a patient treated once will experience the syndrome are greater by at least 111% compared to the correintravenously for 3 days followed by slow taper (50% of the dose every 3 days). All patients responded within 24 sponding odds for a patient treated two or more times. Therefore, we conclude patients with breast cancer and with h, including one patient who required ventilatory support. These patients are alive and well 1-3 years from transplant.
only one previous treatment regimen were more likely to have the syndrome. Since the recognition of the syndrome, we have treated three patients who had simultaneous fever and skin rash Because of concerns regarding the potential confounding of cancer type and gender (lymphoma patients consisted of with or without diarrhea or PTR. All patients received 1 mg/kg/day of methylprednisolone intravenously and both males and females while breast cancer patients consisted entirely of females), we compared syndrome risk responded promptly within 24-48 h. In all patients, no infectious etiology was identified. The length of treatment between female breast cancer patients (20 out of 30 had the syndrome) and female lymphoma patients (one out of with steroids in these patients was no longer than 2 weeks.
five patients had the syndrome) and syndrome risk between female lymphoma patients (one out of five had the Effects of clinical variables on the development of the syndrome) and male lymphoma patients (two out of five syndrome had the syndrome). We note that the pattern of difference in syndrome risk between breast cancer and lymphoma In order to investigate if any of the clinical variables were predictive for increased risk of developing the syndrome, patients is in a similar direction both overall and in females only, but that the difference for females only failed to achiwe compared the incidence of the syndrome by different disease (breast vs lymphoma), source of stem cells (BMeve significance (P = 0.134), very likely due to the even smaller sample size granted by the female stratum. The pat-PBSC vs PBSC), sex (female vs male), extent of previous therapy (only one regimen vs уtwo regimens), and number tern of difference in syndrome risk between females and males overall and between female and male lymphoma of mononuclear cells reinfused (above vs lower than the median number). The results show significance for disease patients was also similar in direction, although neither com-105 Table 5 Predictive factors for the development of the syndrome parison yielded statistically significance difference (P = ture of DAH, rather than ARDS, an entity in which treatment with high-dose steroids is indicated and known to be 1.0).
effective. 16 Indeed, all three patients in our series responded to steroids, and a fourth patient, who was transplanted before the syndrome was recognized and therefore did not Discussion receive steroids, died with respiratory failure. Variable incidence of DAH in autotransplants was reported before with In this report, we describe a clinical syndrome in which the main clinical manifestation is a maculopapular rash comhigh mortality rates. [18] [19] [20] An association with the reappearance of white blood cells was noticed before; however, the monly associated with fever which appears around the time of engraftment of autologous stem cell transplantation.
etiology and the pathogenesis of DAH have not been identified. Because of the association with engraftment and the histologic and clinical appearance of the rash that resemble that Our study suggests that patients with breast cancer are at higher risk for developing the syndrome in comparison of GVHD rash, we have referred to this syndrome as the autoaggression GVHD-like syndrome. A recent report by to lymphoma patients. Furthermore, patients who received уtwo previous regimens of therapy are at significantly Lee et al 17 described a similar syndrome and called it the engraftment syndrome. These authors reported skin rash decreased risk for developing the syndrome (P = 0.002, Table 5 ). Source of stem cells, total mononuclear cell numand fever in 132 patients out of 248 patients (58.9 Ϯ 6.4%) who had autologous BM and/or PBSC transplantation and ber reinfused or sex did not play a role in determining the risk for the syndrome. All patients received G-CSF and included mainly patients with breast cancer, lymphoma, and sarcomas, as well as five miscellaneous patients. The therefore it was unlikely that G-CSF had contributed to the development of the syndrome. The above analysis shows median time to the onset of the engraftment syndrome was 7 days (range 4-22 days) post-transplant. They also that breast cancer patients, who are generally less heavily pretreated, are at increased risk for the syndrome, while reported an incidence of 87.5 Ϯ 4.3% of capillary leak at the time of engraftment with 79 patients suffering from lymphoma patients, who are usually heavily pretreated and therefore may be more profoundly immunosuppressed, are hypoxia, 16 patients developing ARDS requiring ventilation, and five deaths due to ARDS. Four of the patients at significantly lower risk for the development of the syndrome after autologous stem cell transplantation (P = 0.02, who died with ARDS did not receive steroids. Although the incidence and the time of onset of the engraftment syn- Table 5 ). Our findings lead us to the hypothesis that in this patient drome reported by these authors seem similar to that in our series, the incidence of the pulmonary complications in our population the peripheral regulatory mechanism (the safeguard for self-tolerance) is suppressed by the high-dose series was significantly less. This difference could be in part due to the different toxicity profiles of the different chemotherapy given before stem cell transplantation, allowing for the expansion of autoreactive effector T lymconditioning regimens used in their largely heterogeneous group of patients. In contrast, all patients in our study were phocytes during hematopoietic recovery and leading to variable manifestations of the autoaggression syndrome. treated similarly using STAMP V conditioning regimen. In addition, we describe here a clinical and bronchoscopic picSuch a hypothesis could also explain the higher frequency mechanism remains the challenge for future studies.
